Padua Prediction Score for Risk of Venous Thromboembolism (VTE)

Risk stratification model for VTE in hospitalized adult medical patients.

Clinical parameters

Active cancer: local or distant metastases and/or chemotherapy or radiotherapy within the previous 6 months

No0Yes+3

Required

Previous VTE, excluding superficial vein thrombosis

No0Yes+3

Required

Reduced mobility: bed rest with bathroom privileges for at least 3 days

No0Yes+3

Required

Known thrombophilia: antithrombin, protein C or protein S deficiency; factor V Leiden; prothrombin G20210A mutation; or antiphospholipid syndrome

No0Yes+3

Required

Recent trauma and/or surgery within the previous month

No0Yes+2

Required

Age 70 years or older

No0Yes+1

Required

Heart failure and/or respiratory failure

No0Yes+1

Required

Acute myocardial infarction and/or ischemic stroke

No0Yes+1

Required

Acute infection and/or rheumatologic disorder

No0Yes+1

Required

Obesity: body mass index (BMI) 30 kg/m² or greater

No0Yes+1

Required

Ongoing hormonal treatment

No0Yes+1

Required

Score result

0 of 11 score components complete0 / 11

0 / 11

Complete all required parameters to calculate the score.

Still required

Active cancer: local or distant metastases and/or chemotherapy or radiotherapy within the previous 6 months
Previous VTE, excluding superficial vein thrombosis
Reduced mobility: bed rest with bathroom privileges for at least 3 days
Known thrombophilia: antithrombin, protein C or protein S deficiency; factor V Leiden; prothrombin G20210A mutation; or antiphospholipid syndrome
Recent trauma and/or surgery within the previous month
Age 70 years or older
Heart failure and/or respiratory failure
Acute myocardial infarction and/or ischemic stroke
Acute infection and/or rheumatologic disorder
Obesity: body mass index (BMI) 30 kg/m² or greater
Ongoing hormonal treatment

Clinical context

Use the Padua Prediction Score for VTE risk stratification in hospitalized adult medical patients. It does not diagnose VTE and does not replace clinical judgment, bleeding-risk assessment, contraindication review, or the applicable institutional prophylaxis protocol.